Standard Biotools Inc (LAB)

$2.33

-0.03

(-1.27%)

Market is closed - opens 7 PM, 13 Jun 2024

Insights on Standard Biotools Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 25.36M → 45.54M (in $), with an average increase of 24.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -19.77M → -32.15M (in $), with an average decrease of 62.6% per quarter

  • Vs A

    In the last 1 year, Agilent Technologies Inc. has given 11.4% return, outperforming this stock by 3.6%

  • Vs TMO

    In the last 3 years, Standard Biotools Inc has experienced a drawdown of -61.3%, however Thermo Fisher Scientific, Inc. resisted the overall trend and outperformed by 53.3%

Performance

  • $2.30
    $2.43
    $2.33
    downward going graph

    1.18%

    Downside

    Day's Volatility :5.25%

    Upside

    4.12%

    downward going graph
  • $1.57
    $3.16
    $2.33
    downward going graph

    32.62%

    Downside

    52 Weeks Volatility :50.32%

    Upside

    26.27%

    downward going graph

Returns

PeriodStandard Biotools IncSector (Health Care)Index (Russel 2000)
3 Months
-11.94%
-0.5%
0.0%
6 Months
7.76%
9.6%
0.0%
1 Year
7.76%
11.8%
0.0%
3 Years
-61.44%
17.5%
-24.3%

Highlights

Market Capitalization
891.5M
Book Value
$1.23
Earnings Per Share (EPS)
-1.0
Wall Street Target Price
3.58
Profit Margin
-70.98%
Operating Margin TTM
-29.42%
Return On Assets TTM
-9.39%
Return On Equity TTM
-22.74%
Revenue TTM
126.8M
Revenue Per Share TTM
0.95
Quarterly Revenue Growth YOY
-14.2%
Gross Profit TTM
-1.4M
EBITDA
-81.1M
Diluted Eps TTM
-1.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.05
EPS Estimate Next Year
-0.2
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    83%Buy
    16%Hold
    0
    0%Sell
Based on 6 Wall street analysts offering stock ratings for Standard Biotools Inc(by analysts ranked 0 to 5 stars)
Based on 6 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
5
4
4
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 53.65%

Current $2.33
Target $3.58

Company Financials

FY18Y/Y Change
Revenue
113.0M
↑ 10.82%
Net Income
-59.0M
↓ 2.51%
Net Profit Margin
-52.24%
↑ 7.14%
FY19Y/Y Change
Revenue
117.2M
↑ 3.79%
Net Income
-64.8M
↑ 9.79%
Net Profit Margin
-55.26%
↓ 3.02%
FY20Y/Y Change
Revenue
138.1M
↑ 17.83%
Net Income
-53.0M
↓ 18.17%
Net Profit Margin
-38.38%
↑ 16.88%
FY21Y/Y Change
Revenue
130.6M
↓ 5.47%
Net Income
-59.2M
↑ 11.73%
Net Profit Margin
-45.36%
↓ 6.98%
FY22Y/Y Change
Revenue
97.9M
↓ 24.99%
Net Income
-190.1M
↑ 220.91%
Net Profit Margin
-194.08%
↓ 148.72%
FY23Y/Y Change
Revenue
106.3M
↑ 8.57%
Net Income
-74.7M
↓ 60.73%
Net Profit Margin
-70.21%
↑ 123.87%
Q4 FY22Q/Q Change
Revenue
27.0M
↑ 5.36%
Net Income
-20.8M
↓ 29.16%
Net Profit Margin
-77.14%
↑ 37.6%
Q1 FY23Q/Q Change
Revenue
25.1M
↓ 7.04%
Net Income
-16.8M
↓ 19.2%
Net Profit Margin
-67.05%
↑ 10.09%
Q2 FY23Q/Q Change
Revenue
27.7M
↑ 10.14%
Net Income
-17.0M
↑ 1.17%
Net Profit Margin
-61.59%
↑ 5.46%
Q3 FY23Q/Q Change
Revenue
25.4M
↓ 8.31%
Net Income
-21.0M
↑ 23.22%
Net Profit Margin
-82.77%
↓ 21.18%
Q4 FY23Q/Q Change
Revenue
28.2M
↑ 11.12%
Net Income
-19.8M
↓ 5.82%
Net Profit Margin
-70.16%
↑ 12.61%
Q1 FY24Q/Q Change
Revenue
45.5M
↑ 61.56%
Net Income
-32.2M
↑ 62.61%
Net Profit Margin
-70.61%
↓ 0.45%
FY18Y/Y Change
Total Assets
303.6M
↑ 5.67%
Total Liabilities
231.5M
↓ 9.7%
FY19Y/Y Change
Total Assets
264.8M
↓ 12.79%
Total Liabilities
111.2M
↓ 51.97%
FY20Y/Y Change
Total Assets
324.8M
↑ 22.64%
Total Liabilities
185.7M
↑ 67.0%
FY21Y/Y Change
Total Assets
275.2M
↓ 15.26%
Total Liabilities
180.6M
↓ 2.74%
FY22Y/Y Change
Total Assets
390.3M
↑ 41.82%
Total Liabilities
471.8M
↑ 161.2%
FY23Y/Y Change
Total Assets
323.1M
↓ 17.23%
Total Liabilities
159.9M
↓ 66.11%
Q4 FY22Q/Q Change
Total Assets
390.3M
↓ 5.93%
Total Liabilities
471.8M
↓ 1.23%
Q1 FY23Q/Q Change
Total Assets
371.7M
↓ 4.78%
Total Liabilities
468.8M
↓ 0.63%
Q2 FY23Q/Q Change
Total Assets
355.8M
↓ 4.26%
Total Liabilities
469.2M
↑ 0.09%
Q3 FY23Q/Q Change
Total Assets
339.3M
↓ 4.65%
Total Liabilities
471.0M
↑ 0.38%
Q4 FY23Q/Q Change
Total Assets
323.1M
↓ 4.78%
Total Liabilities
159.9M
↓ 66.06%
Q1 FY24Q/Q Change
Total Assets
777.7M
↑ 140.71%
Total Liabilities
200.4M
↑ 25.33%
FY18Y/Y Change
Operating Cash Flow
-25.2M
↑ 4.58%
Investing Cash Flow
4.7M
↓ 73.28%
Financing Cash Flow
57.7M
↑ 98.85%
FY19Y/Y Change
Operating Cash Flow
-35.2M
↑ 39.72%
Investing Cash Flow
-39.3M
↓ 932.82%
Financing Cash Flow
2.8M
↓ 95.16%
FY20Y/Y Change
Operating Cash Flow
-15.4M
↓ 56.21%
Investing Cash Flow
40.0M
↓ 201.71%
Financing Cash Flow
20.9M
↑ 647.56%
FY21Y/Y Change
Operating Cash Flow
-44.1M
↑ 185.79%
Investing Cash Flow
-11.9M
↓ 129.88%
Financing Cash Flow
16.0M
↓ 23.48%
FY22Y/Y Change
Operating Cash Flow
-89.4M
↑ 102.83%
Investing Cash Flow
-88.1M
↑ 637.71%
Financing Cash Flow
230.8M
↑ 1345.94%
Q4 FY22Q/Q Change
Operating Cash Flow
-19.2M
↓ 22.06%
Investing Cash Flow
-88.1M
↓ 920.86%
Financing Cash Flow
-270.0K
↑ 5300.0%
Q1 FY23Q/Q Change
Operating Cash Flow
-8.5M
↓ 55.76%
Investing Cash Flow
43.2M
↓ 148.97%
Financing Cash Flow
-2.6M
↑ 847.41%
Q2 FY23Q/Q Change
Operating Cash Flow
-9.3M
↑ 9.95%
Investing Cash Flow
40.1M
↓ 7.02%
Financing Cash Flow
-2.1M
↓ 18.53%
Q3 FY23Q/Q Change
Operating Cash Flow
-11.4M
↑ 22.33%
Investing Cash Flow
33.4M
↓ 16.88%
Financing Cash Flow
-1.2M
↓ 44.15%

Technicals Summary

Sell

Neutral

Buy

Standard Biotools Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Standard Biotools Inc
Standard Biotools Inc
-4.84%
7.76%
7.76%
-61.44%
-80.48%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
0.63%
-7.13%
9.93%
-14.55%
90.98%
Agilent Technologies Inc.
Agilent Technologies Inc.
-10.59%
2.58%
11.45%
-8.5%
87.95%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
-2.51%
15.79%
9.97%
22.51%
101.91%
Danaher Corp.
Danaher Corp.
3.83%
18.89%
9.75%
5.59%
88.26%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
-5.91%
-0.88%
1.7%
-11.85%
54.05%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Standard Biotools Inc
Standard Biotools Inc
NA
NA
NA
0.05
-0.23
-0.09
NA
1.23
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
49.25
49.25
4.75
11.05
0.72
0.23
NA
18.93
Agilent Technologies Inc.
Agilent Technologies Inc.
31.31
31.31
2.7
5.23
0.21
0.08
0.01
21.31
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
37.32
37.32
2.81
21.72
0.14
0.05
0.0
119.24
Danaher Corp.
Danaher Corp.
48.56
48.56
3.13
7.61
0.08
0.04
0.0
72.16
Iqvia Holdings Inc.
Iqvia Holdings Inc.
29.44
29.44
1.33
11.08
0.22
0.05
NA
34.82
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Standard Biotools Inc
Standard Biotools Inc
Buy
$891.5M
-80.48%
NA
-70.98%
Idexx Laboratories, Inc.
Idexx Laboratories, Inc.
Buy
$42.0B
90.98%
49.25
23.26%
Agilent Technologies Inc.
Agilent Technologies Inc.
Buy
$38.5B
87.95%
31.31
18.84%
Thermo Fisher Scientific, Inc.
Thermo Fisher Scientific, Inc.
Buy
$222.0B
101.91%
37.32
14.2%
Danaher Corp.
Danaher Corp.
Buy
$196.0B
88.26%
48.56
18.55%
Iqvia Holdings Inc.
Iqvia Holdings Inc.
Buy
$39.3B
54.05%
29.44
9.01%

Company Information

fluidigm (nasdaq:fldm) develops, manufactures and markets microfluidic systems for growth markets in the life sciences and in applied markets. fluidigm’s systems consist of instruments, software, integrated fluidic circuits (ifcs), high-performance assays for gene expression and genotyping, and primers for sample preparation for next-generation sequencing. fluidigm technology enables customers to perform thousands of sophisticated biochemical measurements in parallel on samples smaller than the content of a single cell, with nanoliter volumes of reagents, in half the area of a credit card. the company’s integrated customer solutions are designed to significantly simplify experimental workflows, increase throughput and reduce costs while delivering excellent data quality. based in south san francisco, fluidigm offers an exciting and collegial working environment with excellent compensation and benefits, including equity.

Organization
Standard Biotools Inc
Employees
534
CEO
Dr. Michael Egholm Ph.D.
Industry
Technology

FAQs